TY - CHAP M1 - Book, Section TI - Sentinel Node Mapping in Lung Cancer A1 - Colson, Yolonda L. A1 - Liptay, Michael J. A1 - Gilmore, Denis A2 - Sugarbaker, David J. A2 - Bueno, Raphael A2 - Colson, Yolonda L. A2 - Jaklitsch, Michael T. A2 - Krasna, Mark J. A2 - Mentzer, Steven J. A2 - Williams, Marcia A2 - Adams, Ann PY - 2015 T2 - Adult Chest Surgery, 2e AB - Early in the nineteenth century, Virchow implicated lymph nodes in the process of the local spread of solid tumors to a more widespread systemic disease. The node identified by Virchow is specifically located in the left supraclavicular region. In the modern vernacular, the term sentinel lymph node (SLN) describes the first lymph node to receive drainage from any solid tumor in any anatomic region. It was not until 1989 that the concept of SLN biopsy, as it is currently known, was first made popular based on studies by Morton et al.1 A feasibility study using blue dye was translated into a successful clinical trial in patients with melanoma. Their results indicated that biopsy and analysis of SLNs accurately reflected the tumor status of the lymph node basin. SLN biopsy was introduced in breast cancer patients shortly thereafter.2 Further studies supported SLN biopsy as a way to identify patients at highest risk for locoregional recurrence and metastatic spread, and, therefore, most likely to benefit from adjuvant therapy. SLN mapping aids in the identification of lymph nodes at highest risk of metastasis and allows for more detailed analysis to detect early metastatic disease thus identifying patients who may benefit from adjuvant therapy. While SLN biopsy is standard in both breast cancer and melanoma patients, a number of factors have led to slower adoption in patients with non-small cell lung cancer (NSCLC). SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/10/11 UR - accesssurgery.mhmedical.com/content.aspx?aid=1105848028 ER -